Adjuvant Chemotherapy Use for Hormone Receptor–Positive, <i>ERBB2</i> -Negative Breast Cancer After RxPONDER Trial
This retrospective cohort study found that adjuvant chemotherapy use almost doubled in premenopausal patients with node-positive tumors and with a low to intermediate genomic risk from 2019 to 2022 but decreased for patients with node-negative disease, coinciding with the publication of the TAILORx and RxPONDER trials. The findings highlight the variability in genomic assay use to facilitate adjuvant therapy recommendations for HR-positive, ERBB2-negative breast cancer.
Authors
- Poornima Saha (ORCID: https://orcid.org/0009-0005-6609-7188)
- Frederick M. Howard (ORCID: https://orcid.org/0000-0002-6039-1141)
- Daniel S. Peiffer (ORCID: https://orcid.org/0000-0001-6620-7264)
- Sudha Yarlagadda (ORCID: https://orcid.org/0000-0002-5314-7175)
- Sarah P. Shubeck (ORCID: https://orcid.org/0000-0001-8831-2428)
- Jincong Q. Freeman (ORCID: https://orcid.org/0000-0002-1119-2146)
- Dezheng Huo
- Rita Nanda
- Nan Chen
Institutions
- NorthShore University HealthSystem (US)
- Chicago Department of Public Health (US)
- University of Chicago (US)
- Illinois Arts Council Agency (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-12-23
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.49109
- Citations
- 3
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.81